Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  stage III perihilar bile duct cancer
Stage/Subtype:  stage III perihilar bile duct cancer
Trial Type:  Treatment
Results 1-25 of 25 for your search:
Start Over
Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: CDM00047339, NCI-2016-00348, E7059, NCT01774019
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Pembrolizumab, Combination Chemotherapy, and Celecoxib in Treating Patients with Advanced Colorectal, Appendix, Gastroesophageal, Pancreatic, or Biliary Tract Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HCI76239, NCI-2015-00123, MK-3475 GI, 3475-085, 76239, NCT02268825
Regorafenib in Treating Patients With Advanced or Metastatic Biliary Tract Cancer Who Failed First-Line Chemotherapy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 13-100, NCI-2014-01117, NCT02053376
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-17651, NCI-2014-00956, 14.02.0015, NCT02115542
Ponatinib Hydrochloride in Treating Patients with Advanced Biliary Cancer with FGFR2 Fusions
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1345, NCI-2014-02075, NCT02265341
Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients with Advanced or Metastatic Biliary Cancers
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0524, NCI-2015-00578, NCT02392637
Dasatinib in Treating Patients with Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery and with an IDH Mutation
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-007, NCI-2015-00938, CA180-603, NCT02428855
RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RRx001-27-01, NCI-2015-00944, NCT02452970
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PM1183-B-005-14, NCI-2015-01172, NCT02454972
Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LOXO-TRK-15002, NCI-2015-01947, NCT02576431
Copanlisib, Gemcitabine, and Cisplatin in Treating Patients with Advanced Cholangiocarcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-18435, NCI-2016-01029, NCT02631590
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16329, NCI-2016-01171, I3O-MC-JSBF, 2015-004699-31, NCT02711553
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-18684, NCI-2016-01424, NCT02829918
Combination Chemotherapy in Treating Patients With Previously Untreated Locally Advanced or Metastatic Gastrointestinal Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-0033, NCI-2012-00585, 12-0033-AM010, NCT01643499
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI608-246, NCI-2015-00892, NCT02024607
Alisertib and Combination Chemotherapy in Treating Patients with Gastrointestinal Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9824, NCI-2014-02475, VICC GI1536, NCT02319018
Ropidoxuridine in Treating Patients with Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9882, NCI-2015-00258, BRUOG 265, NCT02381561
Afatinib Dimaleate and Capecitabine in Treating Patients with Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 9078, NCI-2015-00684, NCT02451553
Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PM60184-A-003-14, NCI-2015-01510, 2014-002943-16, NCT02533674
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16209, NCI-2016-01101, I6F-MC-JJCD, 2015-004421-14, NCT02784795
Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients with Unresectable or Metastatic Cholangiocarcinoma
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1542, NCI-2016-01057, NCT02856568
6,8-Bis(benzylthio)octanoic Acid in Treating Patients with Advanced or Metastatic Cholangiocarcinoma that Cannot Be Removed by Surgery
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 to 80
Trial IDs: CCCWFU 59212, NCI-2013-00063, NCT01766219
Tremelimumab with Transarterial Chemoembolization, Radiofrequency Ablation, Cryosurgery, or Stereotactic Body Radiation Therapy in Treating Patients with Advanced Liver or Biliary Tract Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-C-0120, NCI-2013-01557, 130120, P121113, NCT01853618
Durvalumab and Tremelimumab with and without Ablative Therapy in Treating Patients with Advanced Liver or Biliary Tract Cancer
Status: Not yet active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-C-0135, NCI-2016-01061, NCT02821754
Start Over